Roche faces setback as crenezumab fails in Alzheimer's study, AC Immune stock slumps 22%

Jun. 16, 2022 4:54 AM ETRoche Holding AG (RHHBY), RHHBF, ACIUBy: Ravikash, SA News Editor2 Comments

Sunset view of riverside of Rhine dominated by the Roche tower in Switzerland

trabantos/iStock via Getty Images

Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) said its medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer's disease in a study.

The results are a setback for the Swiss

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.